# Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia

> **NCT05941156** · PHASE2 · RECRUITING · sponsor: **The Affiliated Hospital of Xuzhou Medical University** · enrollment: 20 (estimated)

## Conditions studied

- Extranodal NK T Cell Lymphoma
- NK-Cell Leukemia

## Interventions

- **BIOLOGICAL:** Anti-CD56 CAR T

## Key facts

- **NCT ID:** NCT05941156
- **Lead sponsor:** The Affiliated Hospital of Xuzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05941156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05941156, "Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05941156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*